Mira Precision Health, Based in Mason, Ohio, Announces U.S. Launch of ToxNav® Advantage™ at the 2026 ASCO® GI Cancers Symposium
PR Newswire —
Expanded pharmacogenomic panel enhances safety for patients receiving 5-FU and capecitabine MASON, Ohio, Jan. 5, 2026 /PRNewswire/ -- Mira Precision Health today announced the official U.S. launch of ToxNav® Advantage™, a clinically validated pharmacogenomic assay designed to identify...